CS1-relaterat
Exploratory outcomes of CS1 in Pulmonary Arterial Hypertension: Phase 2A, Prospective, Randomized, Open-Label, Multicenter Trial
Raymond L. Benza, Marc A. Simon, Selim R. Krim, H. James Ford, Tatiane Abreu Dall-Agnol, Sandhya Murthy, Evelyn Horn, Jason L. Guichard. 4th Balthic Conference on May 9, 2025. [Abstract Book, page 11].
Investigation of efficacy, safety and optimal dose of CS1 in subjects with pulmonary arterial hypertension: a prospective, randomized, multicenter, parallel-group phase II study
Raymond Benza, Niklas Bergh, Philip Adamson, Björn Dahlöf. PVRI congress 2022.
A First in Class Treatment for Thrombosis Prevention. A Phase I study with CS1, a New Controlled Release Formulation of Sodium Valproate
Niklas Bergh, Jan-Peter Idström, Henri Hansson, Jonas Faijerson-Säljö, Björn Dahlöf.
Journal of Cardiology and Vascular Medicine 2019 Volume 5: 1-12.
CS014-relaterat
Novel HDAC inhibitor, CS014, attenuates in vivo thrombosis while maintaining hemostasis
Stanger L, Yalavarthi P, Adili R, Gilmore D, Hoang T, Campbell A, Krenik P, Gustafsson D, Fryklund J, Fex T, Oakes N, Säljö JF, Dahlöf B, Beckman J, Holinstat M. Journal of Thrombosis and Haemostasis (2026), doi: https://doi.org/10.1016/j.jtha.2025.11.011.
HDACi, CS014, dose-dependently reverses vascular remodeling in a preclinical model of pulmonary arterial hypertension [poster presentation]
Tatiane Abreu Dall’Agnol, Fredrik Frick, Rahul Agrawal, Björn Dahlöf, Nicholas Oakes. Presenterat på Pharmacology 2025, 16-18 december, Belfast, Irland.
Safety, tolerability, and pharmacokinetics of the novel HDAC inhibitor CS014: a first-in-human trial [muntlig presentation]
Tatiane Abreu Dall’Agnol, Fredrik Frick, Rahul Agrawal, Björn Dahlöf, Johan Nilsson, Johan Bylund, Erik Westrin, Nicholas Oakes. Presenterat på Pharmacology 2025, 16-18 december, Belfast, Irland.
Epigenetisk modulering och HDAC-hämmare
Histone deacetylase inhibitors for cardiovascular conditions and healthy longevity.
João Pedro Ferreira, Bertram Pitt, Faiez Zannad.
The Lancet Healthy Longevity, Volume 2, Issue 6, 2021, pages e371-e379, ISSN 2666-7568, doi.org/10.1016/S2666-7568(21)00061-1.
CS585-relaterat
CS585 is a first-in-class compound targeting the IP receptor for prevention of thrombosis without increased risk of bleeding
Sylviane Lambert, Reheman Adili, Pooja Yalavarthi, Nicole Rhoads, Björn Dahlöf, Andrew White, Niklas Bergh, Michael Holinstat. HemaSphere, 2022; 6:S3.